Efficacy of Sunitinib in treating metastatic non-clear cell renal cell carcinoma
10.3760/cma.j.issn.1000-6702.2011.10.023
- VernacularTitle:舒尼替尼治疗转移性非透明细胞肾癌的疗效观察
- Author:
Guohai SHI
;
Xudong YAO
;
Shilin ZHANG
;
Bo DAI
;
Hailiang ZHANG
;
Yijun SHEN
;
Yao ZHU
;
Yiping ZHU
;
Chunguang MA
;
Wenjun XIAO
;
Xiaojian QIN
;
Guowen LIN
;
Lifeng YANG
;
Dingwei YE
- Publication Type:Journal Article
- Keywords:
Kidney neoplasms;
Carcinoma;
Metastasis;
Sunitinib
- From:
Chinese Journal of Urology
2011;32(10):711-713
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of Sunitinib in treating metastatic non-clear cell renal cell carcinoma (RCC).Methods Twenty-two metastatic non-clear cell subtype renal cell carcinoma patients with a median age of 46 years (29 -76 years) were treated with Sunitinib.Fourteen cases were found have metastasis post radical nephrectomy,and the remaining eight cases with metastasis received cytoreductive surgery.Pathological diagnosis showed 12 papillary RCCs,one chromophobe RCC,three collecting duct RCCs,and six unclassified RCCs.The metastatic lesions were located in the lung,lymph nodes,adrenal gland,bone,liver,and thyroid gland.The patients were given the treatment of sunitinib 50 mg qd four weeks on and two weeks off.The median time of treatment was 11 months (4.5 - 24 months).Results The objective control rate was 73％.Three papillary RCC and one chromophobe RCC reached partial remission (PR) and 12 cases maintained stable disease (SD) for more than 12 weeks.And the remaining six cases progressed (PD).Conclusions Sunitinib has definitive efficacy in metastatic papillary RCC,chromophobe RCC,collecting duct RCC and unclassified RCC.Metastatic lesions in lungs and lymph nodes might be more sensitive to Sunitinib.
